Atomoxetine for ADHD Treatment

Mechanism of Action and Classification

• Atomoxetine is a selective norepinephrine reuptake inhibitor that increases both noradrenaline and dopamine in the prefrontal cortex, working by selectively binding to norepinephrine transporters, which are also responsible for dopamine reuptake in the prefrontal cortex 1

Key Advantages Over Psychostimulants

Dosing Convenience

• Provides "around-the-clock" effects for ADHD symptoms 2
• Maximum recommended dosage is 1.4 mg/kg/day or 100 mg/day, whichever is lower 1

Comorbid Conditions

• May be beneficial in patients with ADHD and comorbid anxiety disorders 2
• Can be used in patients with tic disorders where stimulants might exacerbate symptoms 3

Efficacy Considerations

• Takes longer to achieve full therapeutic effect (6-12 weeks) compared to stimulants which work rapidly 2

Safety Profile and Monitoring

• Patients starting atomoxetine should be monitored closely for suicidality, clinical worsening, or unusual changes in behavior, especially during the first few months of treatment 4

Pregnancy and Postpartum Considerations

• Limited data suggest atomoxetine does not appear to be associated with major congenital malformations or other significant adverse obstetrical outcomes 5
• A recent large, well-controlled study demonstrated no increased risks for long-term neurodevelopmental outcomes with atomoxetine use during pregnancy 5
• Caution is advised during breastfeeding as effects on nursing infants are unknown 5

Clinical Decision Algorithm

• Consider atomoxetine as first-line when patient has comorbid anxiety disorders 2
• Consider atomoxetine as first-line when patient has tic disorders 3
• Monitor for liver function in patients with preexisting liver disease 6